A. van Oosterom - Concepedia

Author

A. van Oosterom

Also Known As

A T van Oosterom, A Van Oosterom, A van Oosterom, A. Van Oosterom, A. van Oosterom, Allan Oosterom, Allan Van Oosterom, Allan van Oosterom, G.D. Demetri, M. Eldar

136

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

KU Leuven European Organisation for Research and Treatment of Cancer Universitair Ziekenhuis Leuven Antwerp University Hospital The Netherlands Cancer Institute

About

A. van Oosterom is an author at KU Leuven specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	39	3.5K
2	Health Sciences	6	6	730
3	Engineering	1	1	107
4	Natural Sciences	1	1	107
5	Public Health	1	1	39

A. van Oosterom

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®) Sigrid Stroobants, J. Goeminne, M. Seegers, European Journal of Cancer Oncologic ImagingMedical ImagingImatinib MesylateMedicinePathology	2003	526
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez, Gastroenterology Pkc412 InhibitorImatinib-resistant MutantsGastrointestinal OncologyMedicinePathology	2005	492
Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225 Grant A. McArthur, George D. Demetri, A. van Oosterom, Journal of Clinical Oncology	2005	477
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial Axel Le Cesne, Jean‐Yves Blay, Ian Judson, Journal of Clinical Oncology	2005	418
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target Jaap Verweij, A. van Oosterom, Jean‐Yves Blay, European Journal of Cancer OncologyGastrointestinal OncologyMolecular TargetMedicinePathology	2003	402
Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate Hans Prenen, Jan Cools, Nicole Mentens, Clinical Cancer Research	2006	275
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group Axel Le Cesne, Ian Judson, D. Crowther, Journal of Clinical Oncology	2000	255
Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas Vivien Bramwell, Henning T. Mouridsen, Armando Santoro, European Journal of Cancer and Clinical Oncology Surgical OncologyCyclophosphamide Versus IfosfamideMedicineFinal ReportMetronomic Therapy	1987	242
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity Maria Dêbiec‐Rychter, Bartosz Wasąg, Michel Stul, The Journal of Pathology	2004	214
Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases Michael C. Heinrich, Heikki Joensuu, George D. Demetri, Clinical Cancer Research	2008	212

Page 1